HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome

Bone Marrow Transplantation

Volumn 45, Issue 8, 2010, Pages 1333-1339

  Chen, Y ^a   Liu, K ^a   Xu, L ^a   Chen, H ^a   Liu, D ^a   Zhang, X ^a   Shi, H ^a   Han, W ^a   Wang, Y ^a   Zhao, T ^a   Wang, J ^a   Huang, X ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

allogeneic; haploidentical; hematopoietic SCT; HLA; mismatched; myelodysplastic syndrome

Indexed keywords

ACICLOVIR; BASILIXIMAB; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACLIZUMAB; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; MEPREDNISONE; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; ENGRAFTMENT; ENTERITIS; FEMALE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HLA MATCHING; HLA MISMATCHING; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; RELAPSE; T CELL DEPLETION; TREATMENT RESPONSE;

ADULT; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955581737     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.351     Document Type: Article

References (28)

1. Fukumoto JS, Greenber PL. Management of patients with higher risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2005; 56: 179-192.
2. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291-297.
3. Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Huan C, Wei H et al. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008; 40: 444-455.
4. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. The French-American-British(FAB) Co-Operative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
5. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW et al. Myeodyaplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. LARC Press: Lyon, 2001. pp 61-73.
6. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndrome. Blood 1997; 89: 2079-2088.
7. Martin P, Nash R, Sanders J, Leisenring W, Anasetti C, Deeg HJ et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplantation 1998; 92: 2303-2314.
8. Sullivan KM. Graft-versus-host-disease. In Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation. 2nd edn. Blackwell Science: Boston, MA, 1999, 515-536.
9. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/ haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007, 414-417. (Pubitemid 350143554)
10. Elfenbein GJ, Sackatein R. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow. Exp Hematol 2004; 2: 27-339.
11. Huang XJ, Chang YJ, Zhao XY. A direct comparison of immunological characteristics of granulocyte-colony stimulating factor (G-CSF)-primed bone marrow grafts and G-CSF-mobilized peripheral blood grafts. Hematologica 2005; 90: 715-716.
12. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporespon- siveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2007; 17: 193-197.
13. Sierra J, Perez WS, Rozman C, Carreras E, Klein JP, Rizzo JD et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997-2004.
14. Mattijssen V, Schattenberg A, Schaap N, Preijers F, De Witte T. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelo- dysplastic syndromes. Bone Marrow Transplant 1997; 19: 791-794.
15. Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A et al. Bone marrow transplantation from HLA- identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 255-261.
16. de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2000; 110: 620-630.
17. Castro-Malaspina H, Harris RE, Gajewski J, Ramsay N, Collins R, Dharan B et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99: 1943-1951.
18. de Witte T, Pikkemaat F, Hermans J, van Biezen A, Mackinnan S, Cornelissen J et al. Genotypically nonidentical related donors for transplantation of patients with myelodys- plastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. Leukemia 2001; 15: 1878-1884.
19. Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002; 99: 4370-4378.
20. Zhao XY, Chang YJ, Huang XJ. Effects of rhG-CSF mobilization on immunological properties of grafts from peripheral blood and bone marrow. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006; 14: 787-790.
21. Huang XJ, Chang YJ, Zhao XY. Hyporesponsiveness and polarization potential of T cells after in vitro mixture of G- CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2007; 17: 193-197.
22. Martino R, van Biezen A, Iacobelli S, Brand R, Niederwieser DW, de Witte T. Reduced-intensity conditioning (RIC) for allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings in adults with myelodysplastic syndrome (MDS). A comparison with standard myeloablative conditioning: a study of the EBMT-Chronic Leukemia Working Party (EBMT-CLWP). Abstracts for the 45th annual meeting of the American Society of Hematology. Blood 2003; 102: 184a.
23. Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI et al. Allogeneic marrow transplantation for myelodysplastic syndromes with advanced disease morphology: a phase II study of bsulfan, cyclophosphamide, and total- body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220-226.
24. Xu LP, Huang XJ, Liu KY, Chen H, Liu DH, Han W et al. Allogeneic stem cell transplantation from genotypically HLA-identical siblings for 30 patients with myelodysplastic syndromes. zhonghua Xue Ye Xue Za Zhi 2006; 27: 518-520.
25. Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA- identical sibling donor for myelodysplastic syndrome. Leukemia 2005; 19: 396-401.
26. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodys- plastic syndrome. Blood 2002; 100: 1201-1207.
27. Scott BL, Storer B, Loken MR, Storb R, Appelbaum FR, Deeg HJ. Pretransplantation in induction chemotherapy and post- rransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005; 11: 65-73.
28. CIBMTR Newsletter July 2008. http://www.cibmtr.org/PUBLICATIONS/ Newsletter/DOCS/2008Jul.pdf